ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1–SHP2 Signaling Pathway in Non-Small Cell Lung Cancer

The drug resistance of first-line crizotinib therapy for ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) fusion non-small cell lung cancer (NSCLC) is inevitable. Whether the administration of immune checkpoint inhibitor (ICI) therapy is suitable for ROS 1 fusion NSCLCs or after the development...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Liangliang, Duan, Jianchun, Qian, Li, Wang, Zhijie, Wang, Shuhang, Li, Sini, Wang, Chao, Zhao, Jie, Zhang, Xue, Bai, Hua, Wang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723923/
https://www.ncbi.nlm.nih.gov/pubmed/33324391
http://dx.doi.org/10.3389/fimmu.2020.527750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723923/
https://www.ncbi.nlm.nih.gov/pubmed/33324391
http://dx.doi.org/10.3389/fimmu.2020.527750

Ejemplares similares